Trelegy Ellipta can be prescribed at general hospitals
By Eo, Yun-Ho | translator Choi HeeYoung
21.09.21 17:08:26
가나다라
0
It passed DC of 38 medical institutions nationwide, including SNUH and AMC
In a study reflecting the clinical practice environment, the efficacy of improving lung function was confirmed
According to related industries, GSK Korea's COPA treatment Trelegy Ellipta (Fluticasone Furoate,
Umecridinium Br, Villanterol Trifenate) passed DC at 38 medical institutions including Big 5 General Hospitals such as Seoul National University Hospital and Asan Medical Center. Since the insurance benefits in June, prescriptions have become possible quickly.
Trelegy Ellipta is the first COPD complex approved in Korea in May 2018. It is prescribed as a maintenance therapy for moderate and severe COPD that is not properly controlled by persistent β2 agonist and inhalation corticosteroid combination therapy or
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)